Psoriasis biosimilars and pricing changes herald treatment paradigm disruptions
Experts predict that physicians may favour emerging biosimilar versions of Stelara over more effective originator IL-23 drugs.
Pricing and Market Access
South Korean pricing reform suggests more flexible drug reimbursement negotiations
Unresolved clawback issues obstruct Greece’s potential pharmaceutical framework agreement
Keytruda and Opdivo: a decade review
US negotiations for first round of drugs reveal $6bn in Medicare savings
Colombia’s president signs law to strengthen pharmaceutical sector
Casgevy: Launch sequence and price analysis of the first marketed CRISPR therapy
The US Biosecure Act threatens to destabilise the pharmaceutical industry
